Our partners

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. They aim to positively impact the health of 2.5 billion people by the end of 2030. GSK’s bold ambitions for patients are reflected in commitments to growth and a step-change in performance.

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023.

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has three highly differentiated clinical programs ongoing in retinitis pigmentosa, cataracts and cystinosis with the potential to be first-of-a-kind therapies and gateways to wider applications. Based in Fort Worth, TX, the company has extensive managerial and scientific domain expertise as well as backing from Foundation Fighting Blindness (https://www.fightingblindness.org) and its venture arm RD Fund (https://www.retinaldegenerationfund.org).

TargTex SA is a portuguese biotech company founded in 2019 that emerged from a blended academic research and medical environment. Its basic technology was developed in Gonçalo Bernardes research lab at Instituto de Medicina Molecular (iMM) of the University of Lisbon.

Its foundation is based on an artificial intelligence algorithm created by one of the founding members that can decipher relationships between biological targets and molecules of interest. Hence, it was possible to identify an unexplored target for a daunting pathology – Glioblastoma Multiforme (GBM). Considering GBM’s particularities, a hydrogel to be used as adjunct-to-surgery in a single dose therapy is being developed as a solution.

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

Aprecia is reimagining medicine so patients and caregivers can live their best lives. Demand for life changing, patient-centric medicines has never been greater, and our breakthrough 3D-Printing (3DP) technology expands the possibilities. Our proprietary production systems and formulation platforms set a new standard in modern pharmaceutics, creating better products in better ways. Aprecia is the only company in the world to scale-up manufacturing for a 3DP product, win regulatory approval, and reliably produce commercial supply. We see many opportunities for our technology to take existing medicines to their full potential and accelerate a new spectrum of product development possibilities. Aprecia directly owns a patent estate for novel 3DP equipment and pharmaceutical applications. Pharmaceutical partners can license our exclusive technology platforms and contract our beginning to end specialty development, manufacturing and support services.

The Bill & Melinda Gates Foundation is a nonprofit fighting poverty, disease, and inequity around the world. For over 20 years, the Bill & Melinda Gates Foundation has been committed to tackling the greatest inequities in our world. It focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Co-chairs Bill Gates and Melinda French Gates and the board of trustees.

Celanese Corporation is a global leader in the production of differentiated chemistry solutions and specialty materials. Its pharmaceutical business, under the VitalDose® brand, works with strategic partners to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Based in Dallas, TX, Celanese employs approximately 13,000 employees worldwide and had 2022 net sales of $9.7 billion